Alexion Reports First Quarter 2017 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Alexion Pharma (ALXN) Tops Q1 EPS by 15c; Raises Outlook
April 27, 2017 6:32 AM EDTAlexion Pharma (NASDAQ: ALXN) reported Q1 EPS of $1.38, $0.15 better than the analyst estimate of $1.23. Revenue for the quarter came in at $870 million versus the consensus estimate of $827.2 million.
1Q17 Total Revenues of $870 Million, a 24% Increase and 26% Volume Increase Year-Over-YearRevenue Growth Benefited from Continued Strong Volume Growth of Soliris® In Core MarketsStrensiq® Revenue Driven by Steady Addition of New Patients Starting... More